Introducing a New Era in Precision Diagnostics at JHAH: Our First In-house Molecular Oncology Test Result
March 11, 2026
Johns Hopkins Aramco Healthcare has reached a major milestone in its diagnostic capabilities with the successful introduction and reporting of its first molecular oncology test result. This achievement marks a significant step forward in our precision‑medicine journey and reflects our commitment to providing patients with faster, more accurate and more personalized cancer diagnostics.
A New Diagnostic Frontier: What the Test Is
The newly introduced test is a Microsatellite Instability (MSI) analysis, performed using the Idylla™ MSI platform, an automated molecular testing system designed for rapid and reliable genetic profiling. MSI testing examines specific DNA regions, microsatellites, to determine whether they are stable or unstable. Instability in these regions can indicate defects in the DNA mismatch‑repair system, a key factor in several cancers.
The test is performed on FFPE tissue samples and evaluates seven MSI biomarkers. In this first case, all seven biomarkers were successfully amplified, confirming the test’s validity.
What the Result Shows
The first test result was Microsatellite Stable (MSS), meaning no mutations were detected in any of the seven MSI biomarkers and there is no evidence of microsatellite instability. This finding is clinically important because MSI status directly influences treatment decisions, prognosis and eligibility for certain therapies.
Why MSI Testing Matters for Our Patients
MSI testing is a cornerstone in modern oncology because it helps guide treatment pathways across several cancer types, including colorectal, endometrial and gastric cancers. Its clinical value includes identifying candidates for immunotherapy, supporting accurate diagnosis
and prognosis and improving personalized treatment planning. By offering MSI testing in‑house, JHAH reduces waiting times, eliminates the need for external referrals and ensures faster clinical decision‑making.
A Significant Step Forward for JHAH’s Diagnostic Services
Introducing molecular oncology mutation testing represents a major enhancement in the services we provide. It demonstrates advanced diagnostic capability aligned with international standards, improved turnaround times, enhanced precision in cancer care and greater autonomy within our pathology and oncology services. This achievement also aligns with JHAH’s broader strategic direction, expanding into a regional center of excellence and elevating the quality of care through innovation.
“Being part of this breakthrough in molecular diagnostics has been truly inspiring,” said Bashayer Al Shehri, Lab Technologist, Laboratory Department. “Introducing this capability means we can deliver critical genetic insights with greater speed and accuracy, and that progress will make a real difference in patient care.”
What This Means for the Future
The successful completion of our first MSI test is only the beginning. It paves the way for additional molecular panels such as KRAS, NRAS, BRAF and EGFR, broader access to targeted therapies, stronger integration between pathology, oncology and precision medicine and a more comprehensive cancer diagnostic program within JHAH. As we continue to expand our molecular testing portfolio, patients will benefit from earlier detection, more accurate diagnoses and treatments tailored to their unique genetic profiles.